H3K27M drives OPC stemness and intrathecal therapeutic vulnerability in brainstem glioma organoids.

H3K27M-mutant brainstem glioma organoids reveal OPC stemness driven by dysregulated ACTIVIN signaling and identify effective intrathecal therapy.

• Why it matters: Brainstem gliomas are difficult to treat due to their location, blood-brain barrier, and resistance, and existing models poorly mimic the tumor environment, hindering therapy development.
• What they did: Researchers developed a high-success patient-derived organoid platform that preserves tumor features and used multi-omics and functional assays to uncover OPC stemness mechanisms, then screened intrathecal drugs.
• The result: The study identified triple intrathecal therapy (methotrexate, cytarabine, dexamethasone) as effective against DMGs, with personalized organoid-guided treatment showing sustained responses and CSF proteomics tracking therapy efficacy.